08 — Statin Intolerance
Table of Contents
1.0 Overview
Statin intolerance is a common clinical challenge, reported by 5–30% of patients depending on the definition used [1]. The most frequent complaint is statin-associated muscle symptoms (SAMS). This pathway provides a structured approach to evaluating and managing statin intolerance at The Sandusky Dyslipidemia Model clinic.
See the Statin Intolerance Flowchart for a visual representation.
1.1 Key Principles
- Patient symptoms alone are sufficient to document statin intolerance at this clinic. Symptom scores (e.g., SAMS-CI) are available but not required.
- One-time rechallenge with a different statin is attempted before moving to alternative agents.
- If the rechallenge is not tolerated, the patient is transitioned to a statin-free regimen without further statin attempts.
2.0 Definition of Statin Intolerance
For the purposes of this clinic, statin intolerance is defined as:
The inability to tolerate at least one statin at any dose due to symptoms or objective findings (e.g., CK elevation) that resolve or improve upon discontinuation and recur upon rechallenge or, at the patient’s report, are attributed to the statin.
The nocebo effect (expectation-driven side effects) accounts for a significant proportion of statin-related complaints. The SAMSON trial demonstrated that approximately 90% of the symptom burden attributed to statins was also present during placebo periods [2]. Providers should acknowledge patient symptoms while being aware of this phenomenon.
3.0 Initial Evaluation
3.1 Characterize the Symptoms
| Assessment | Details |
|---|---|
| Symptom type | Myalgia, myopathy, weakness, fatigue, GI symptoms, cognitive complaints, other |
| Onset timing | Relative to statin initiation or dose change |
| Which statin(s) | Specific agents and doses previously tried |
| Duration of each trial | How long the patient took the statin before discontinuation |
| Resolution after discontinuation | Did symptoms resolve, and how quickly? |
3.2 Rule Out Secondary Causes of Myalgia
Before attributing symptoms to the statin, evaluate for conditions that mimic or exacerbate statin-related myopathy:
| Secondary Cause | Evaluation |
|---|---|
| Hypothyroidism | TSH (untreated hypothyroidism increases myopathy risk) |
| Vitamin D deficiency | 25-OH vitamin D (low levels associated with myopathy) |
| Drug interactions | Review for CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors, grapefruit juice) and CYP2C9 inhibitors affecting specific statins |
| Renal impairment | eGFR (impaired clearance of statin metabolites) |
| Hepatic impairment | Hepatic panel |
| Concurrent medications | Fibrates (especially gemfibrozil), cyclosporine, niacin at high doses |
| Polymyalgia rheumatica or other rheumatologic conditions | ESR, CRP if clinically suspected |
| Physical overexertion | History (recent intense exercise) |
| Alcohol excess | History |
3.3 Creatine Kinase (CK) Assessment
| Scenario | Action |
|---|---|
| Symptoms with no CK elevation (CK < 4× ULN) | Most common presentation; myalgia without myopathy |
| CK 4–10× ULN with symptoms | True statin myopathy; discontinue statin; recheck CK in 2–4 weeks |
| CK > 10× ULN | Rhabdomyolysis risk; discontinue statin immediately; IV fluids, monitor renal function |
| CK elevation without symptoms | Mild elevation may be incidental; investigate other causes; do not necessarily attribute to statin |
3.4 Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)
The SAMS-CI is a validated tool to assess the likelihood that muscle symptoms are attributable to statin therapy [3]. It evaluates symptom characteristics, timing, and dechallenge/rechallenge results.
| Score | Interpretation |
|---|---|
| ≥ 9 | Probable statin-related |
| 7–8 | Possible statin-related |
| < 7 | Unlikely statin-related |
Use of the SAMS-CI is optional at this clinic. It is available as a supportive tool but is not required for documenting statin intolerance. Patient-reported symptoms are accepted.
4.0 One-Time Rechallenge Protocol
All patients reporting statin intolerance are offered a single rechallenge with a different statin before moving to statin-free alternatives.
4.1 Rechallenge Strategy
| Parameter | Approach |
|---|---|
| Statin selection | Choose a different statin than the one causing symptoms. Preferred: rosuvastatin or pitavastatin (lower myopathy risk) [4]. If the patient was previously on rosuvastatin, try pitavastatin or low-dose atorvastatin. |
| Dose | Start at the lowest available dose |
| Frequency | May use alternate-day dosing (e.g., rosuvastatin 5 mg every other day) for the rechallenge period [5] |
| Duration | Trial period of 4–8 weeks |
| Patient counseling | Explain the nocebo effect; set expectations; encourage full trial period before judging tolerability |
| Monitoring | Check in at 2–4 weeks (phone or visit) to assess tolerability |
4.2 Rechallenge Outcomes
| Outcome | Action |
|---|---|
| Tolerated | Continue and titrate upward toward highest tolerated dose; recheck lipids in 4–8 weeks |
| Not tolerated | Discontinue; document as confirmed statin intolerance; proceed to statin-free regimen (Section 5.0) |
Only one rechallenge is attempted. If the rechallenge fails, the patient is not subjected to additional statin trials. The focus shifts to statin-free alternatives.
5.0 Statin-Free Regimen
For patients with confirmed statin intolerance after one failed rechallenge, the following statin-free regimen is used:
5.1 First-Line Statin-Free Therapy
| Agent | Dose | Expected LDL-C Reduction | Notes |
|---|---|---|---|
| Ezetimibe | 10 mg daily | 15–20% | Well-tolerated; no muscle effects |
| Bempedoic acid | 180 mg daily | 15–25% | No muscle activation (prodrug activated only in liver); CLEAR Outcomes evidence [6] |
| Ezetimibe + bempedoic acid (Nexlizet) | 10 mg / 180 mg daily | 35–40% combined | Fixed-dose combination; convenient |
5.2 Escalation in Statin-Free Patients
If LDL-C/ApoB not at target on ezetimibe + bempedoic acid:
| Step | Agent | Additional LDL-C Reduction |
|---|---|---|
| Add PCSK9 inhibitor | Evolocumab 140 mg SC q2 weeks or alirocumab 75–150 mg SC q2 weeks | 50–60% |
| OR Add inclisiran | 284 mg SC at Day 0, Day 90, then q6 months | ~50% |
5.3 Maximum Statin-Free Regimen
The maximum statin-free regimen at this clinic:
Ezetimibe 10 mg daily + Bempedoic acid 180 mg daily + PCSK9 inhibitor (or inclisiran)
This combination can achieve LDL-C reductions of 70–80% from untreated baseline.
6.0 Documentation Requirements
For prior authorization and clinical documentation:
| Element | Required Documentation |
|---|---|
| Statin(s) tried | Name, dose, duration of each trial |
| Symptoms reported | Type, severity, onset timing |
| Objective findings | CK level if checked (not required) |
| Resolution after discontinuation | Time to symptom resolution |
| Rechallenge attempt | Which statin, dose, duration, outcome |
| SAMS-CI score | Optional but supports documentation |
This documentation is critical for prior authorization of PCSK9 inhibitors and inclisiran (see 11 — Prior Authorization).
7.0 Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-03-30 | Initial release |
References
- Banach M, Rizzo M, Toth PP, et al. Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.
- Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects (SAMSON). N Engl J Med. 2020;383(22):2182–2184.
- Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–186.
- Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance (GAUSS-3). JAMA. 2016;315(15):1580–1590.
- Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42(3):341–346.
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353–1364.